Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease

References

• Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatol Baltim Md. 2016;64:1577–1586.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatol Baltim Md. 2012;55:2005–2023.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL). Electronic address: [email protected], European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402..
   PubMed Web of Science ®Google Scholar
• Roeb E, Steffen HM, Bantel H, et al. [S2k guideline non-alcoholic fatty liver disease]. Z Gastroenterol. 2015;53:668–723.
   PubMed Web of Science ®Google Scholar
• Jahn D, Rau M, Wohlfahrt J, et al. Non-alcoholic steatohepatitis: from pathophysiology to novel therapies. Dig Dis Basel Switz. 2016;34:356–363.
   PubMed Web of Science ®Google Scholar
• Fierbinteanu-Braticevici C, Negreanu L, Tarantino G. Is fatty liver always benign and should not consequently be treated? J. Physiol Pharmacol Off J Pol Physiol Soc. 2013;64:3–9.
   PubMed Web of Science ®Google Scholar
• Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol Baltim Md. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Bieghs V, Van Gorp PJ, Wouters K, et al. LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS One. 2012;7:e30668.
   PubMed Web of Science ®Google Scholar
• Yoshimatsu M, Terasaki Y, Sakashita N, et al. Induction of macrophage scavenger receptor MARCO in nonalcoholic steatohepatitis indicates possible involvement of endotoxin in its pathogenic process. Int J Exp Pathol. 2004;85:335–343.
   PubMed Web of Science ®Google Scholar
• Kong B, Luyendyk JP, Tawfik O, et al. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther. 2009;328:116–122.
   PubMed Web of Science ®Google Scholar
• Tetri LH, Basaranoglu M, Brunt EM, et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295:G987–995.
   PubMed Web of Science ®Google Scholar
• Dowman JK, Hopkins LJ, Reynolds GM, et al. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol. 2014;184:1550–1561.
   PubMed Web of Science ®Google Scholar
• Kohli R, Kirby M, Xanthakos SA, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatol Baltim Md. 2010;52:934–944.
   PubMed Web of Science ®Google Scholar
• Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2011;301:G825–834.
   PubMed Web of Science ®Google Scholar
• Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26:549–564.
   PubMed Web of Science ®Google Scholar
• Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016;65:579–588.
   PubMed Web of Science ®Google Scholar
• Mayer J, Bates MW, Dickie MM. Hereditary diabetes in genetically obese mice. Science. 1951;113:746–747.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1–16.
   PubMed Web of Science ®Google Scholar
• Leclercq IA, Farrell GC, Schriemer R, et al. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol. 2002;37:206–213.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatol Baltim Md. 2003;37:544–550.
   PubMed Web of Science ®Google Scholar
• Uygun A, Kadayifci A, Yesilova Z, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2000;95:3584–3589.
   PubMed Web of Science ®Google Scholar
• Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science. 1966;153:1127–1128.
   PubMed Web of Science ®Google Scholar
• Sahai A, Malladi P, Pan X, et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1035–1043.
   PubMed Web of Science ®Google Scholar
• Zucker LM. Hereditary obesity in the rat associated with hyperlipemia. Ann N Y Acad Sci. 1965;131:447–458.
   PubMed Web of Science ®Google Scholar
• Phillips MS, Liu Q, Hammond HA, et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet. 1996;13:18–19.
   PubMed Web of Science ®Google Scholar
• Schreyer SA, Vick C, Lystig TC, et al. LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am J Physiol Endocrinol Metab. 2002;282:E207–214.
   PubMed Web of Science ®Google Scholar
• Ioannou GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab TEM. 2016;27:84–95.
   PubMed Web of Science ®Google Scholar
• Ibrahim SH, Hirsova P, Malhi H, et al. Animal models of nonalcoholic steatohepatitis: eat, delete, and inflame. Dig Dis Sci. 2016;61:1325–1336..
   PubMed Web of Science ®Google Scholar
• Yao ZM, Vance DE. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem. 1988;263:2998–3004.
   PubMed Web of Science ®Google Scholar
• Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 1996;111:1645–1653.
   PubMed Web of Science ®Google Scholar
• Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105:1067–1075.
   PubMed Web of Science ®Google Scholar
• Kulinski A, Vance DE, Vance JE. A choline-deficient diet in mice inhibits neither the CDP-choline pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion. J Biol Chem. 2004;279:23916–23924.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Elias MS, Smolak RR, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008;49:1068–1076.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004;40:47–51.
   PubMed Web of Science ®Google Scholar
• Vornoli A, Pozzo L, Della Croce CM, et al. Drug metabolism enzymes in a steatotic model of rat treated with a high fat diet and a low dose of streptozotocin. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc. 2014;70:54–60.
   PubMed Web of Science ®Google Scholar
• Patoine D, Levac X, Pilote S, et al. Decreased CYP3A expression and activity in guinea pig models of diet-induced metabolic syndrome: is fatty liver infiltration involved? Drug Metab. Dispos Biol Fate Chem. 2013;41:952–957. .
   PubMed Web of Science ®Google Scholar
• Donato MT, Lahoz A, Jiménez N, et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos Biol Fate Chem. 2006;34:1556–1562.
   PubMed Web of Science ®Google Scholar
• Donato MT, Jiménez N, Serralta A, et al. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol Vitro Int J Publ Assoc BIBRA. 2007;21:271–276.
   PubMed Web of Science ®Google Scholar
• Kolwankar D, Vuppalanchi R, Ethell B, et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:388–393.
   PubMed Web of Science ®Google Scholar
• Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos Biol Fate Chem. 2009;37:2087–2094.
   PubMed Web of Science ®Google Scholar
• Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1281–1287.
   PubMed Web of Science ®Google Scholar
• Lake AD, Novak P, Fisher CD, et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos Biol Fate Chem. 2011;39:1954–1960.
   PubMed Web of Science ®Google Scholar
• Dietrich CG, Geier A, Salein N, et al. Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2. Gastroenterology. 2004;126:1044–1053.
   PubMed Web of Science ®Google Scholar
• Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis II Cytochrome P-450 Enzymes Oxidative Stress . Am J Physiol Gastrointest Liver Physiol. 2001;281:G1135–1139..
   PubMed Web of Science ®Google Scholar
• Fisher CD, Jackson JP, Lickteig AJ, et al. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol. 2008;82:959–964.
   PubMed Web of Science ®Google Scholar
• Woolsey SJ, Mansell SE, Kim RB, et al. CYP3A activity and expression in nonalcoholic fatty liver disease. Drug Metab Dispos Biol Fate Chem. 2015;43:1484–1490.
   PubMed Web of Science ®Google Scholar
• Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatol Baltim Md. 1998;27:128–133.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141.
   PubMed Web of Science ®Google Scholar
• Orellana M, Rodrigo R, Varela N, et al. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res Off J Jpn Soc Hepatol. 2006;34:57–63.
   PubMed Web of Science ®Google Scholar
• Abdelmegeed MA, Banerjee A, Jang S, et al. CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic Biol Med. 2013;65:1238–1245.
   PubMed Web of Science ®Google Scholar
• Niemelä O, Parkkila S, Juvonen RO, et al. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol. 2000;33:893–901.
   PubMed Web of Science ®Google Scholar
• Osabe M, Sugatani J, Fukuyama T, et al. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab Dispos Biol Fate Chem. 2008;36:294–302.
   PubMed Web of Science ®Google Scholar
• Dzierlenga AL, Clarke JD, Hargraves TL, et al. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. J Pharmacol Exp Ther. 2015;352:462–470.
   PubMed Web of Science ®Google Scholar
• Jia X, Naito H, Yetti H, et al. Dysregulated bile acid synthesis, metabolism and excretion in a high fat-cholesterol diet-induced fibrotic steatohepatitis in rats. Dig Dis Sci. 2013;58:2212–2222.
   PubMed Web of Science ®Google Scholar
• Uchaipichat V, Mackenzie PI, Guo X-H, et al. Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos Biol Fate Chem. 2004;32:413–423.
   PubMed Web of Science ®Google Scholar
• Dietrich CG, Geier A, Wasmuth HE, et al. Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen. Gut. 2004;53:1850–1855.
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Ferreira DW, More VR, et al. Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos Biol Fate Chem. 2013;41:554–561.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatol Baltim Md. 2005;42:665–674.
   PubMed Web of Science ®Google Scholar
• Canet MJ, Merrell MD, Hardwick RN, et al. Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis. Drug Metabolism and Disposition. 2015;43:829–835.
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology. 2004;126:322–342.
   PubMed Web of Science ®Google Scholar
• Geier A, Wagner M, Dietrich CG, et al. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochimica Et Biophysica Acta (BBA) Molecular Cell Research. 2007;1773:283–308.
   PubMed Web of Science ®Google Scholar
• Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatol Baltim Md. 2001;33:633–646.
   PubMed Web of Science ®Google Scholar
• Zollner G, Wagner M, Fickert P, et al. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int Off J Int Assoc Study Liver. 2007;27:920–929.
   PubMed Web of Science ®Google Scholar
• Takeyama Y, Uehara Y, Inomata S, et al. Alternative transporter pathways in patients with untreated early-stage and late-stage primary biliary cirrhosis. Liver Int Off J Int Assoc Study Liver. 2009;29:406–414.
   PubMed Web of Science ®Google Scholar
• Hanada K, Nakai K, Tanaka H, et al. Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet. 2012;27:301–306.
   PubMed Web of Science ®Google Scholar
• Nakai K, Tanaka H, Hanada K, et al. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos Biol Fate Chem. 2008;36:1786–1793.
   PubMed Web of Science ®Google Scholar
• Geier A, Dietrich CG, Grote T, et al. Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol. 2005;43:1021–1030.
   PubMed Web of Science ®Google Scholar
• Pizarro M, Balasubramaniyan N, Solís N, et al. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut. 2004;53:1837–1843.
   PubMed Web of Science ®Google Scholar
• Fisher CD, Lickteig AJ, Augustine LM, et al. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol. 2009;613:119–127.
   PubMed Web of Science ®Google Scholar
• Inaba R, Inaba M, Iwamura K. Light microscopic and electron microscopic study on morphologic features resulting in the delay of ICG elimination in diabetic and non-diabetic fatty liver. Tokai J Exp Clin Med. 1984;9:207–216.
   PubMedGoogle Scholar
• Canet MJ, Hardwick RN, Lake AD, et al. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Drug Metab Dispos Biol Fate Chem. 2014;42:586–595.
   PubMed Web of Science ®Google Scholar
• Renaud HJ, Cui JY, Lu H, et al. Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis. PLoS One. 2014;9:e88584.
   PubMed Web of Science ®Google Scholar
• Martin IV, Schmitt J, Minkenberg A, et al. Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice. Biol Chem. 2010;391:1441–1449.
   PubMed Web of Science ®Google Scholar
• More VR, Slitt AL. Alteration of hepatic but not renal transporter expression in diet-induced obese mice. Drug Metab Dispos Biol Fate Chem. 2011;39:992–999.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Aleksunes LM, Manautou JE, et al. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm. 2008;5:77–91.
   PubMed Web of Science ®Google Scholar
• Kulkarni SR, Xu J, Donepudi AC, et al. Effect of caloric restriction and AMPK activation on hepatic nuclear receptor, biotransformation enzyme, and transporter expression in lean and obese mice. Pharm Res. 2013;30:2232–2247.
   PubMed Web of Science ®Google Scholar
• Hartmann G, Cheung AKY, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002;303:273–281.
   PubMed Web of Science ®Google Scholar
• Geier A, Dietrich CG, Voigt S, et al. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol. 2005;289:G831–841.
   PubMed Web of Science ®Google Scholar
• Yu J, Ip E, Dela Peña A, et al. COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatol Baltim Md. 2006;43:826–836.
   PubMed Web of Science ®Google Scholar
• Oz HS, Im H-J, Chen TS, et al. Glutathione-enhancing agents protect against steatohepatitis in a dietary model. J Biochem Mol Toxicol. 2006;20:39–47.
   PubMed Web of Science ®Google Scholar
• Isoda K, Sawada S, Ayaori M, et al. Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem. 2005;280:7002–7009.
   PubMed Web of Science ®Google Scholar
• Kudo A, Ban D, Aihara A, et al. Decreased Mrp2 transport in severe macrovesicular fatty liver grafts. J Surg Res. 2012;178:915–921.
   PubMed Web of Science ®Google Scholar
• Lickteig AJ, Fisher CD, Augustine LM, et al. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos Biol Fate Chem. 2007;35:1970–1978.
   PubMed Web of Science ®Google Scholar
• Lickteig AJ, Fisher CD, Augustine LM, et al. Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. J Biochem Mol Toxicol. 2007;21:216–220.
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Fisher CD, Canet MJ, et al. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos Biol Fate Chem. 2011;39:2395–2402..
   PubMed Web of Science ®Google Scholar
• Vander Borght S, Libbrecht L, Katoonizadeh A, et al. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J Histochem Cytochem Off J Histochem Soc. 2006;54:1051–1059.
   PubMed Web of Science ®Google Scholar
• Bechmann LP, Kocabayoglu P, Sowa J-P, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatol Baltim Md. 2013;57:1394–1406.
   PubMed Web of Science ®Google Scholar
• Lake AD, Novak P, Shipkova P, et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol. 2013;268:132–140.
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Clarke JD, Lake AD, et al. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Toxicol Sci Off J Soc Toxicol. 2014;142:45–55.
   PubMed Web of Science ®Google Scholar
• Tsuda N, Matsui O. Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression. Eur Radiol. 2011;21:2542–2550.
   PubMed Web of Science ®Google Scholar
• Marin D, Iannaccone R, Catalano C, et al. Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images. J Magn Reson Imaging JMRI. 2006;24:690–694.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Kishimoto S, Shibatani N, et al. The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. J Pharm Pharmacol. 2010;62:310–314.
   PubMed Web of Science ®Google Scholar
• Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol. 1992;34:130–138.
   PubMed Web of Science ®Google Scholar
• Fujita K, Ando Y, Yamamoto W, et al. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol. 2010;65:251–258.
   PubMed Web of Science ®Google Scholar
• Ferslew BC, Johnston CK, Tsakalozou E, et al. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. Clin Pharmacol Ther. 2015;97:419–427.
   PubMed Web of Science ®Google Scholar
• Zelcer N, Van De Wetering K, Hillebrand M, et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci U S A. 2005;102:7274–7279.
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Fisher CD, Street SM,et al. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos Biol Fate Chem. 2012;40:450–460..
   PubMed Web of Science ®Google Scholar
• Takeshita Y, Takamura T, Honda M, et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia. 2014;57:878–890.
   PubMed Web of Science ®Google Scholar
• Li P, Robertson TA, Thorling CA, et al. Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Drug Metab Dispos Biol Fate Chem. 2011;39:571–579.
   PubMed Web of Science ®Google Scholar
• Kulkarni NM, Malampati S, Mahat MYA, et al. Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease. Drug Metab Pers Ther. 2016;31:165–171.
   PubMedGoogle Scholar
• Zhou X, Lra R, Bedwell DW, et al. Difference in the pharmacokinetics and hepatic metabolism of antidiabetic drugs in Zucker diabetic fatty and Sprague-Dawley rats. Drug Metab Dispos Biol Fate Chem. 2016;44:1184–1192.
   PubMed Web of Science ®Google Scholar
• He L, Liu X, Wang L, et al. Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials. Medicine (Baltimore). 2016;95:e4947.
   PubMed Web of Science ®Google Scholar
• Chen L, Shu Y, Liang X, et al. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A. 2014;111:9983–9988.
   PubMed Web of Science ®Google Scholar
• Jang E-H, Kim H-K, Park C-S, et al. Increased expression of hepatic organic cation transporter 1 and hepatic distribution of metformin in high-fat diet-induced obese mice. Drug Metab Pharmacokinet. 2010;25:392–397.
   PubMed Web of Science ®Google Scholar
• Clarke JD, Dzierlenga AL, Nelson NR, et al. Mechanism of altered metformin distribution in nonalcoholic steatohepatitis. Diabetes. 2015;64:3305–3313.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol. 2014;10:839–857.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet Lond. Engl.. 2016;387:679–690.
   PubMed Web of Science ®Google Scholar
• Firneisz G, Varga T, Lengyel G, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One. 2010;5:e12226.
   PubMed Web of Science ®Google Scholar
• Jung Y-A, Choi Y-K, Jung G-S, et al. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. Diabetes Res Clin Pract. 2014;105:47–57.
   PubMed Web of Science ®Google Scholar
• Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:23–31.
   PubMed Web of Science ®Google Scholar
• Shyangdan D, Clar C, Ghouri N, et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess Winch Engl. 2011;15:1–110.
   PubMed Web of Science ®Google Scholar
• Igel M, Arnold KA, Niemi M, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther. 2006;79:419–426.
   PubMed Web of Science ®Google Scholar
• Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics. 2012;13:579–594.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Johnson SG, Caudle KE, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96:423–428.
   PubMed Web of Science ®Google Scholar
• Clarke JD, Hardwick RN, Lake AD, et al. Synergistic interaction between genetics and disease on pravastatin disposition. J Hepatol. 2014;61:139–147.
   PubMed Web of Science ®Google Scholar
• Clarke JD, Hardwick RN, Lake AD, et al. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression. J Pharmacol Exp Ther. 2014;348:452–458.
   PubMed Web of Science ®Google Scholar
• Szabó M, Veres Z, Bátai-Konczos A, et al. Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes. Toxicol Vitro Int J Publ Assoc BIBRA. 2014;28:1136–1143.
   PubMed Web of Science ®Google Scholar
• Donthamsetty S, Bhave VS, Mitra MS, et al. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate. Toxicol Appl Pharmacol. 2008;230:327–337.
   PubMed Web of Science ®Google Scholar
• Michaut A, Moreau C, Robin M-A, et al. Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int Off J Int Assoc Study Liver. 2014;34:e171–179.
   PubMed Web of Science ®Google Scholar
• Barshop NJ, Capparelli EV, Sirlin CB, et al. Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2011;52:198–202.
   PubMed Web of Science ®Google Scholar
• Aleksunes LM, Campion SN, Goedken MJ, et al. Acquired resistance to acetaminophen hepatotoxicity is associated with induction of multidrug resistance-associated protein 4 (Mrp4) in proliferating hepatocytes. Toxicol Sci Off J Soc Toxicol. 2008;104:261–273.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146:489–503.
   PubMed Web of Science ®Google Scholar
• Dietrich CG, Geier A, Oude Elferink RPJ. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut. 2003;52:1788–1795.
   PubMed Web of Science ®Google Scholar
• Rau R, Karger T, Herborn G, et al. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J Rheumatol. 1989;16:489–493.
   PubMed Web of Science ®Google Scholar
• Aponte J, Petrelli M. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheum. 1988;31:1457–1464.
   PubMed Web of Science ®Google Scholar
• Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111–1118.
   PubMed Web of Science ®Google Scholar
• Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol. 2001;16:1395–1401.
   PubMed Web of Science ®Google Scholar
• Naik A, Belič A, Zanger UM, et al. Molecular interactions between NAFLD and xenobiotic metabolism. Front Genet. 2013;4:2.
   PubMedGoogle Scholar
• van Waterschoot RAB, Lagas JS, Wagenaar E. et al. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int J Cancer. 2010;127:2959–2964..
   PubMed Web of Science ®Google Scholar
• Altaf S, Enders F, Jeavons E, et al. High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2013;60:2042–2046.
   PubMed Web of Science ®Google Scholar
• ZAltaf S, Enders F, Krailo M, et al. Response to “high BMI at diagnosis is associated with inferior survival in patients with osteosarcoma.” Pediatr Blood Cancer. 2014;61:951.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res Off J Jpn Soc Hepatol. 2007;37:410–415.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71–87.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:1553–1561.
   PubMed Web of Science ®Google Scholar
• Surapaneni KM, Priya VV, Mallika J. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH). Eur Rev Med Pharmacol Sci. 2014;18:2736–2741.
   PubMed Web of Science ®Google Scholar
• Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis. 2014;34:205–214.
   PubMed Web of Science ®Google Scholar
• Ohnishi T, Ogawa Y, Saibara T, et al. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients. Oncol Rep. 2005;13:485–489.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Valenti L. Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic fatty liver disease: any role in disease susceptibility?. PPAR Res. 2013;2013:452061.
   PubMed Web of Science ®Google Scholar
• Athinarayanan S, Wei R, Zhang M, et al. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials. PLoS One. 2014;9:e95366.
   PubMed Web of Science ®Google Scholar
• Koutsounas I, Theocharis S, Delladetsima I, et al. Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility. Expert Opin Drug Metab Toxicol. 2015;11:523–532.
   PubMed Web of Science ®Google Scholar
• Canet MJ, Hardwick RN, Lake AD, et al. Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis. Drug Metab Dispos Biol Fate Chem. 2015;43:266–272.
   PubMed Web of Science ®Google Scholar
• Targher G, Chonchol M, Zoppini G, et al. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J. Hepatol. 2011;54:1020–1029..
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Chonchol M, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia. 2010;53:1341–1348.
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Rodella S, et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol CJASN. 2010;5:2166–2171.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet Lond. Engl.. 2010;376:1916–1922.
   PubMed Web of Science ®Google Scholar
• Zamor PJ, Russo MW. Liver function tests and statins. Curr Opin Cardiol. 2011;26:338–341.
   PubMed Web of Science ®Google Scholar
• Nestel PJ, Mensink RP. Perspective: nonalcoholic fatty liver disease and cardiovascular risk. Curr Opin Lipidol. 2013;24:1–3.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet Lond. Engl.. 2015;385:956–965.
   PubMed Web of Science ®Google Scholar
• Clarke JD, Cherrington NJ. Nonalcoholic steatohepatitis in precision medicine: unraveling the factors that contribute to individual variability. Pharmacol Ther. 2015;151:99–106.
   PubMed Web of Science ®Google Scholar